-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Carmustine (BCNU)-based pretreatment regimen is the standard regimen for autologous hematopoietic stem cell transplantation (aHCT) for the treatment of relapsed and refractory non-Hodgkin’s lymphoma (R/R NHL).
Due to the shortage of carmustine in Canada, the price of carmustine has risen sharply.
In May 2015, the Mason-Rosemont Hospital Research Center of the University of Montreal decided to use bendamustine (Benda) instead of aHCT pretreatment program In carmustine.
As a quality control, the center compared the efficacy results of the two pretreatment programs.
The purpose of this retrospective study was to determine the safety and effectiveness of Benda-EAM pretreatment regimen (bendamustine, etoposide, cytarabine, melphalan) before aHCT in the treatment of R/R NHL.
The results of the study will be announced at the 47th Annual Meeting of the European Association of Blood and Bone Marrow Transplantation (EBMT 2021) in 2021.
The editor organizes the main content as follows for the reference of readers.
01 Research method The study reviewed 131 patients who received Benda-EAM pretreatment between May 2015 and May 2018, and 96 patients who received carmustine pretreatment between January 2012 and May 2015 The patients of the protocol were analyzed, and the baseline characteristics, adverse reactions and post-transplant results of the two groups of patients were compared.
02 Results of the study The baseline characteristics of patients in the carmustine group (n=96) and the bendamustine group (n=131) basically matched, and the patients in the bendamustine group were older.
The incidence of adverse reactions was higher in the bendamustine group, among which mucositis, acute renal failure and ICU admission were more common.
Patients in the bendamustine group had a longer hospital stay, but there were no deaths related to the Benda-EAM regimen.
At a median follow-up of 64 months in the carmustine group, the 48-month disease-free survival (DFS) rate was 61%, and the 48-month overall survival (OS) rate was 73%; the bendamustine group had a median follow-up of 36 At 6 months, the 48-month DFS rate was 71%, and the 48-month OS rate was 86% (P=0.
006).
03Research conclusions The use of bendamustine in pre-transplantation pretreatment regimen instead of carmustine can improve the prognosis of patients with R/R NHL, and bendamustine pretreatment regimen can be used as a new standard of treatment.
Reference source: S.
Lachance, A.
Bourguignon, J.
-A.
Boisjoly, et al.
Bendamustine-based conditioning prior to autologous hematopoietic cell transplant improves outcomes in patients with relapsed-refractory non hodgkin lymphoma.
The 47th Annual Meeting of the EBMT .
Abstract OS15-1.
Stamp "read the original text", we make progress together
Due to the shortage of carmustine in Canada, the price of carmustine has risen sharply.
In May 2015, the Mason-Rosemont Hospital Research Center of the University of Montreal decided to use bendamustine (Benda) instead of aHCT pretreatment program In carmustine.
As a quality control, the center compared the efficacy results of the two pretreatment programs.
The purpose of this retrospective study was to determine the safety and effectiveness of Benda-EAM pretreatment regimen (bendamustine, etoposide, cytarabine, melphalan) before aHCT in the treatment of R/R NHL.
The results of the study will be announced at the 47th Annual Meeting of the European Association of Blood and Bone Marrow Transplantation (EBMT 2021) in 2021.
The editor organizes the main content as follows for the reference of readers.
01 Research method The study reviewed 131 patients who received Benda-EAM pretreatment between May 2015 and May 2018, and 96 patients who received carmustine pretreatment between January 2012 and May 2015 The patients of the protocol were analyzed, and the baseline characteristics, adverse reactions and post-transplant results of the two groups of patients were compared.
02 Results of the study The baseline characteristics of patients in the carmustine group (n=96) and the bendamustine group (n=131) basically matched, and the patients in the bendamustine group were older.
The incidence of adverse reactions was higher in the bendamustine group, among which mucositis, acute renal failure and ICU admission were more common.
Patients in the bendamustine group had a longer hospital stay, but there were no deaths related to the Benda-EAM regimen.
At a median follow-up of 64 months in the carmustine group, the 48-month disease-free survival (DFS) rate was 61%, and the 48-month overall survival (OS) rate was 73%; the bendamustine group had a median follow-up of 36 At 6 months, the 48-month DFS rate was 71%, and the 48-month OS rate was 86% (P=0.
006).
03Research conclusions The use of bendamustine in pre-transplantation pretreatment regimen instead of carmustine can improve the prognosis of patients with R/R NHL, and bendamustine pretreatment regimen can be used as a new standard of treatment.
Reference source: S.
Lachance, A.
Bourguignon, J.
-A.
Boisjoly, et al.
Bendamustine-based conditioning prior to autologous hematopoietic cell transplant improves outcomes in patients with relapsed-refractory non hodgkin lymphoma.
The 47th Annual Meeting of the EBMT .
Abstract OS15-1.
Stamp "read the original text", we make progress together
